Abstract
Introduction: Multiple sclerosis is a non-traumatic neurological disease caused by an immune-mediated reaction leading to a chronic inflammatory demyelinating disorder of the central nervous system. The treatments for multiple sclerosis are mainly divided into three categories: treatment of exacerbation, slowing disease progression with disease-modifying therapies, and symptomatic therapies. Natalizumab is a monoclonal antibody that works by preventing the adhesion of lymphocytes into the endothelium of the blood-brain barrier, reducing lymphocyte infiltration into the central nervous system. This review aims to study the efficacy and safety of natalizumab in relapsing-remitting multiple sclerosis. Methods: The review was performed using databases like PubMed, Cochrane library, Google scholar from which 48 relevant articles were selected based on the various inclusion criteria. The following keywords were used: “Natalizumab”, “Multiple sclerosis”, “side effects”, “Relapsing-remitting multiple sclerosis”, “progressive multifocal leukoencephalopathy” in different combinations. Results: The literature review suggests that natalizumab reduces the rate of sustained progression of the disease and disability, and was associated with a lower relapse rate in patients with relapsing-remitting multiple sclerosis. However, Progressive multifocal leukoencephalopathy is one of the serious side effects of natalizumab. Conclusion: The literature review suggests that Natalizumab has favorable outcomes in patients with relapsing-remitting multiple sclerosis. Since progressive multifocal leukoencephalopathy is one of the serious side effects of natalizumab, risk stratification should be done.
Highlights
Multiple sclerosis is a non-traumatic neurological disease caused by an immune-mediated reaction leading to a chronic inflammatory demyelinating disorder of the central nervous system
The effect of NTZ on reducing the annualized relapse rate (ARR) and expanded disability status scale were done (EDSS) progression was further highlighted by the study done by Butzkueven where treatment with NTZ was associated with a lower relapse rate and it helped to stabilize disability levels in patients with RRM.[7]
Association between the clinical and statistical reduction in the risk of progressive multifocal leukoencephalopathy (PML) with extended interval dosing (EID) of NTZ was shown by the study done by Ryerson et al In addition, another retrospective study of Ryerson et al demonstrated that EID reduced the risk of PML without diminishing the clinical efficacy of NTZ in patients with Multiple sclerosis (MS)
Summary
Multiple sclerosis is a non-traumatic neurological disease caused by an immune-mediated reaction leading to a chronic inflammatory demyelinating disorder of the central nervous system. Results: The literature review suggests that natalizumab reduces the rate of sustained progression of the disease and disability, and was associated with a lower relapse rate in patients with relapsing-remitting multiple sclerosis. Conclusion: The literature review suggests that Natalizumab has favorable outcomes in patients with relapsing-remitting multiple sclerosis. Since progressive multifocal leukoencephalopathy is one of the serious side effects of natalizumab, risk stratification should be done. Multiple sclerosis (MS) is an immune mediated chronic inflammatory demyelinating disorder of the central nervous system leading to damage of the axons and progressive neurodegeneration from the early stages. MS has been divided into four different categories as per its presentation pattern which are Relapsing remitting Multiple Sclerosis (RRMS), Secondary progressive Multiple Sclerosis (SPMS), Primary progressive Multiple Sclerosis (PPMS), Progressive relapsing Multiple Sclerosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
